Prognostic role of FDG PET/CT in patients with differentiated thyroid cancer treated with 131-iodine empiric therapy

B. Salvatore, M. Klain, E. Nicolai, D. D'Amico, G. De Matteis, M. Raddi, R. Fonti, T. Pellegrino, G. Storto, A. Cuocolo, L. Pace

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: To assess the long-term prognostic value of 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in patients with differentiated thyroid carcinoma (DTC) undergoing empiric radioiodine (RAI) therapy due to raising values of thyroglobulin (Tg). Methods: Forty-nine patients with histological diagnosis of DTC (31 with papillary and 18 with follicular carcinoma) follow-up for a mean period of 7.9±5 years after empiric RAI therapy were retrospectively analyzed. Results:FDG-PET/CT was negative in 15 (30.6%) patients and positive in 34 (69.4%), whereas postradioiodine therapy whole body scan (t-WBS) was negative in 16 (32.7%) and positive in 33 (67.3%) patients. FDG-PET/CT and t-WBS were in agreement in 32 patients (7 both negative and 25 both positive); on the contrary, in 17 patients there was disagreement between FDG-PET/CT and t-WBS (P=ns). At short-term follow-up, Tg normalized in 19 (38.8%) patients and was unchanged or increased in 30 (61.2%). Of the 15 patients with negative FDG-PET/CT, 11 (73.3%) showed Tg normalization, whereas of the 34 patients with positive FDG-PET/CT, only 8 (23.5%) had Tg normalization (x2=8.9, P<.005). At multivariate analysis, FDG-PET/CT and Tg normalization at short-term follow-up were independent predictors of disease-free survival (x2=26.3, P<.0001), while Tg normalization was the only variable associated with overall survival x2=7.2, P<.01). Conclusion: FDG-PET/CT in association with Tg normalization at short-term follow-up may be useful for long-term prognostic stratification in DTC patients.. © 2017 the Author(s). Published by Wolters Kluwer Health, Inc.
Original languageEnglish
JournalMedicine (United States)
Volume96
Issue number42
DOIs
Publication statusPublished - Oct 2017

Fingerprint

Thyroid Neoplasms
Iodine
Thyroglobulin
Whole Body Imaging
Therapeutics
Positron Emission Tomography Computed Tomography
Fluorodeoxyglucose F18
Disease-Free Survival
Multivariate Analysis
Carcinoma
Survival
Health

Keywords

  • 18F-FDG-PET/CT
  • differentiated thyroid carcinoma
  • empiric therapy
  • prognosis
  • thyroglobulin
  • fluorodeoxyglucose f 18
  • iodine 131
  • radioactive iodine
  • radiopharmaceutical agent
  • adult
  • Article
  • cancer diagnosis
  • cancer patient
  • cancer prognosis
  • cancer survival
  • clinical article
  • differentiated thyroid cancer
  • disease free survival
  • female
  • follow up
  • histopathology
  • human
  • male
  • medical record review
  • middle aged
  • overall survival
  • positron emission tomography-computed tomography
  • priority journal
  • retrospective study
  • thyroglobulin blood level
  • thyroid follicular carcinoma
  • thyroid papillary carcinoma
  • whole body scintiscanning
  • aged
  • biosynthesis
  • diagnostic imaging
  • mortality
  • pathology
  • Thyroid Neoplasms
  • Adult
  • Aged
  • Disease-Free Survival
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Iodine Radioisotopes
  • Male
  • Middle Aged
  • Positron Emission Tomography Computed Tomography
  • Prognosis
  • Radiopharmaceuticals
  • Retrospective Studies
  • Thyroglobulin

Cite this

Prognostic role of FDG PET/CT in patients with differentiated thyroid cancer treated with 131-iodine empiric therapy. / Salvatore, B.; Klain, M.; Nicolai, E.; D'Amico, D.; De Matteis, G.; Raddi, M.; Fonti, R.; Pellegrino, T.; Storto, G.; Cuocolo, A.; Pace, L.

In: Medicine (United States), Vol. 96, No. 42, 10.2017.

Research output: Contribution to journalArticle

@article{91c73558f24d4577ba0e2f93426faa77,
title = "Prognostic role of FDG PET/CT in patients with differentiated thyroid cancer treated with 131-iodine empiric therapy",
abstract = "Background: To assess the long-term prognostic value of 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in patients with differentiated thyroid carcinoma (DTC) undergoing empiric radioiodine (RAI) therapy due to raising values of thyroglobulin (Tg). Methods: Forty-nine patients with histological diagnosis of DTC (31 with papillary and 18 with follicular carcinoma) follow-up for a mean period of 7.9±5 years after empiric RAI therapy were retrospectively analyzed. Results:FDG-PET/CT was negative in 15 (30.6{\%}) patients and positive in 34 (69.4{\%}), whereas postradioiodine therapy whole body scan (t-WBS) was negative in 16 (32.7{\%}) and positive in 33 (67.3{\%}) patients. FDG-PET/CT and t-WBS were in agreement in 32 patients (7 both negative and 25 both positive); on the contrary, in 17 patients there was disagreement between FDG-PET/CT and t-WBS (P=ns). At short-term follow-up, Tg normalized in 19 (38.8{\%}) patients and was unchanged or increased in 30 (61.2{\%}). Of the 15 patients with negative FDG-PET/CT, 11 (73.3{\%}) showed Tg normalization, whereas of the 34 patients with positive FDG-PET/CT, only 8 (23.5{\%}) had Tg normalization (x2=8.9, P<.005). At multivariate analysis, FDG-PET/CT and Tg normalization at short-term follow-up were independent predictors of disease-free survival (x2=26.3, P<.0001), while Tg normalization was the only variable associated with overall survival x2=7.2, P<.01). Conclusion: FDG-PET/CT in association with Tg normalization at short-term follow-up may be useful for long-term prognostic stratification in DTC patients.. {\circledC} 2017 the Author(s). Published by Wolters Kluwer Health, Inc.",
keywords = "18F-FDG-PET/CT, differentiated thyroid carcinoma, empiric therapy, prognosis, thyroglobulin, fluorodeoxyglucose f 18, iodine 131, radioactive iodine, radiopharmaceutical agent, adult, Article, cancer diagnosis, cancer patient, cancer prognosis, cancer survival, clinical article, differentiated thyroid cancer, disease free survival, female, follow up, histopathology, human, male, medical record review, middle aged, overall survival, positron emission tomography-computed tomography, priority journal, retrospective study, thyroglobulin blood level, thyroid follicular carcinoma, thyroid papillary carcinoma, whole body scintiscanning, aged, biosynthesis, diagnostic imaging, mortality, pathology, Thyroid Neoplasms, Adult, Aged, Disease-Free Survival, Female, Fluorodeoxyglucose F18, Humans, Iodine Radioisotopes, Male, Middle Aged, Positron Emission Tomography Computed Tomography, Prognosis, Radiopharmaceuticals, Retrospective Studies, Thyroglobulin",
author = "B. Salvatore and M. Klain and E. Nicolai and D. D'Amico and {De Matteis}, G. and M. Raddi and R. Fonti and T. Pellegrino and G. Storto and A. Cuocolo and L. Pace",
note = "Export Date: 5 March 2018 CODEN: MEDIA Correspondence Address: Salvatore, B.; Istituto di Biostrutture e Bioimmagini, CNRFrance; email: barbara.salvatore@cnr.it Chemicals/CAS: fluorodeoxyglucose f 18, 63503-12-8; iodine 131, 10043-66-0, 15124-39-7; thyroglobulin, 9010-34-8; Fluorodeoxyglucose F18; Iodine Radioisotopes; Radiopharmaceuticals; Thyroglobulin References: Tuttle, R.M., Tala, H., Shah, J., Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: Using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system (2010) Thyroid, 20, pp. 1341-1349; Haugen, B.R., Alexander, E.K., Bible, K.C., 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer (2016) Thyroid, 26, pp. 1-33; Feldt-Rasmussen, U., Schlumberger, M., European interlaboratory comparison of serum thyroglobulin measurement (1998) J Endocrinol Invest, 11, pp. 175-181; Salvatori, M., Biondi, B., Rufini, V., Imaging in endocrinology: 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in differentiated thyroid carcinoma: Clinical indications and controversies in diagnosis and follow-up (2015) Eur J Endocrinol, 173, pp. R115-R130; Asa, S., Aksoy, S.Y., Vatankulu, B., The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 wholebody scan and elevated anti-Tg level (2014) Ann Nucl Med, 28, pp. 970-979; Salvatore, B., Paone, G., Klain, M., Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation (2008) Q J Nucl Med Mol Imaging, 52, pp. 2-8; Wang, W., Larson, S.M., Tuttle, R.M., Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine (2001) Thyroid, 11, pp. 1169-1175; Rosario, P.W., Moura{\~o}, G.F., Dos Santos, J.B., Is empirical radioactive iodine therapy still a valid approach to patients with thyroid cancer and elevated thyroglobulin (2014) Thyroid, 24, pp. 533-536; Kloos, R.T., Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer (2008) J Clin Endocrinol Metab, 93, pp. 1519-1525; Rivera, M., Ghossein, R.A., Schoder, H., Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma (2008) Cancer, 113, pp. 48-56; Pace, L., Klain, M., Salvatore, B., Prognostic role of 18F-FDG PET/CT in the postoperative evaluation of differentiated thyroid cancer patients (2015) Clin Nucl Med, 40, pp. 111-115; Wang, W., Larson, S.M., Fazzari, M., Prognostic value of [18F] fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer (2000) J Clin Endocrinol Metab, 85, pp. 1107-1113; Robbins, R.J., Wan, Q., Grewal, R.K., Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F] fluoro-2-deoxy-Dglucose-positron emission tomography scanning (2006) J Clin Endocrinol Metab, 91, pp. 498-505; Creach, K.M., Nussenbaum, B., Siegel, B.A., Thyroid carcinoma uptake of 18F-Fluorodeoxyglucose in patients with elevated serum thyroglobulin and negative 131I scintigraphy (2013) Am J Otolaryngol, 34, pp. 51-56; Deandreis, D., Al Ghuzlan, A., Leboulleux, S., Do histological immunohistochemical and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome (2011) Endocr Relat Cancer, 18, pp. 159-169; Tomoda, C., Ogimi, Y., Saito, F., Outcome and characteristics of patients with malignant pleural effusion from differentiated thyroid carcinoma (2016) Endocr J, 63, pp. 257-261; Durante, C., Haddy, N., Baudin, E., Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy (2006) JClin Endocrinol Metab, 91, pp. 2892-2899; Dong, M.J., Liu, Z.F., Zhao, K., Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: A meta-analysis (2013) Nucl Med Commun, 30, pp. 639-650; Podoloff, D.A., Ball, D.W., Ben-Josef, E., NCCN task force report: Clinical utility of PET in a variety of tumor types (2009) J Natl Compr Canc Netw, 5, pp. 1-26; Lamartina, L., Deandreis, D., Durante, C., ENDOCRINE TUMOURS: Imaging in the follow up of differentiated thyroid cancer: Current evidence and future perspectives for a risk-adapted approach (2016) Eur J Endocrinol, 175, pp. R185-202; Treglia, G., Giovanella, L., Prognostic role of FDG-PET/CT in differentiated thyroid carcinoma Where are we now (2015) J Med Imaging Radiat Oncol, 59, pp. 278-280; Vural, G.U., Akkas, B.E., Ercakmak, N., Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: Correlation with clinical and histopathologic characteristics and long-termfollow-up data (2012) Clin Nucl Med, 37, pp. 953-959; Schreinemakers, J.M.J., Vriens, M.R., Munoz-Perez, N., Fluorodeoxyglucose-positron emission tomography scan-positive recurrent papillary thyroid cancer and the prognosis and implications for surgical management (2012) World J Surg Oncol, 10, p. 192; Marcus, C., Antoniou, A., Rahmim, A., Fluorodeoxyglucose positron emission tomography/computerized tomography in differentiated thyroid cancer management: Importance of clinical justification and value in predicting survival (2015) J Med Imaging Radiat Oncol, 59, pp. 281-288; Ibanez, E.M., Muros, M.A., Torres Vela, E., The role of early 18F-FDG PET/CT in therapeutic management and ongoing risk stratification of high/intermediate-risk thyroid carcinoma (2016) Endocrine, 51, pp. 490-498",
year = "2017",
month = "10",
doi = "10.1097/MD.0000000000008344",
language = "English",
volume = "96",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "42",

}

TY - JOUR

T1 - Prognostic role of FDG PET/CT in patients with differentiated thyroid cancer treated with 131-iodine empiric therapy

AU - Salvatore, B.

AU - Klain, M.

AU - Nicolai, E.

AU - D'Amico, D.

AU - De Matteis, G.

AU - Raddi, M.

AU - Fonti, R.

AU - Pellegrino, T.

AU - Storto, G.

AU - Cuocolo, A.

AU - Pace, L.

N1 - Export Date: 5 March 2018 CODEN: MEDIA Correspondence Address: Salvatore, B.; Istituto di Biostrutture e Bioimmagini, CNRFrance; email: barbara.salvatore@cnr.it Chemicals/CAS: fluorodeoxyglucose f 18, 63503-12-8; iodine 131, 10043-66-0, 15124-39-7; thyroglobulin, 9010-34-8; Fluorodeoxyglucose F18; Iodine Radioisotopes; Radiopharmaceuticals; Thyroglobulin References: Tuttle, R.M., Tala, H., Shah, J., Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: Using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system (2010) Thyroid, 20, pp. 1341-1349; Haugen, B.R., Alexander, E.K., Bible, K.C., 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer (2016) Thyroid, 26, pp. 1-33; Feldt-Rasmussen, U., Schlumberger, M., European interlaboratory comparison of serum thyroglobulin measurement (1998) J Endocrinol Invest, 11, pp. 175-181; Salvatori, M., Biondi, B., Rufini, V., Imaging in endocrinology: 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in differentiated thyroid carcinoma: Clinical indications and controversies in diagnosis and follow-up (2015) Eur J Endocrinol, 173, pp. R115-R130; Asa, S., Aksoy, S.Y., Vatankulu, B., The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 wholebody scan and elevated anti-Tg level (2014) Ann Nucl Med, 28, pp. 970-979; Salvatore, B., Paone, G., Klain, M., Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation (2008) Q J Nucl Med Mol Imaging, 52, pp. 2-8; Wang, W., Larson, S.M., Tuttle, R.M., Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine (2001) Thyroid, 11, pp. 1169-1175; Rosario, P.W., Mouraõ, G.F., Dos Santos, J.B., Is empirical radioactive iodine therapy still a valid approach to patients with thyroid cancer and elevated thyroglobulin (2014) Thyroid, 24, pp. 533-536; Kloos, R.T., Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer (2008) J Clin Endocrinol Metab, 93, pp. 1519-1525; Rivera, M., Ghossein, R.A., Schoder, H., Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma (2008) Cancer, 113, pp. 48-56; Pace, L., Klain, M., Salvatore, B., Prognostic role of 18F-FDG PET/CT in the postoperative evaluation of differentiated thyroid cancer patients (2015) Clin Nucl Med, 40, pp. 111-115; Wang, W., Larson, S.M., Fazzari, M., Prognostic value of [18F] fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer (2000) J Clin Endocrinol Metab, 85, pp. 1107-1113; Robbins, R.J., Wan, Q., Grewal, R.K., Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F] fluoro-2-deoxy-Dglucose-positron emission tomography scanning (2006) J Clin Endocrinol Metab, 91, pp. 498-505; Creach, K.M., Nussenbaum, B., Siegel, B.A., Thyroid carcinoma uptake of 18F-Fluorodeoxyglucose in patients with elevated serum thyroglobulin and negative 131I scintigraphy (2013) Am J Otolaryngol, 34, pp. 51-56; Deandreis, D., Al Ghuzlan, A., Leboulleux, S., Do histological immunohistochemical and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome (2011) Endocr Relat Cancer, 18, pp. 159-169; Tomoda, C., Ogimi, Y., Saito, F., Outcome and characteristics of patients with malignant pleural effusion from differentiated thyroid carcinoma (2016) Endocr J, 63, pp. 257-261; Durante, C., Haddy, N., Baudin, E., Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy (2006) JClin Endocrinol Metab, 91, pp. 2892-2899; Dong, M.J., Liu, Z.F., Zhao, K., Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: A meta-analysis (2013) Nucl Med Commun, 30, pp. 639-650; Podoloff, D.A., Ball, D.W., Ben-Josef, E., NCCN task force report: Clinical utility of PET in a variety of tumor types (2009) J Natl Compr Canc Netw, 5, pp. 1-26; Lamartina, L., Deandreis, D., Durante, C., ENDOCRINE TUMOURS: Imaging in the follow up of differentiated thyroid cancer: Current evidence and future perspectives for a risk-adapted approach (2016) Eur J Endocrinol, 175, pp. R185-202; Treglia, G., Giovanella, L., Prognostic role of FDG-PET/CT in differentiated thyroid carcinoma Where are we now (2015) J Med Imaging Radiat Oncol, 59, pp. 278-280; Vural, G.U., Akkas, B.E., Ercakmak, N., Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: Correlation with clinical and histopathologic characteristics and long-termfollow-up data (2012) Clin Nucl Med, 37, pp. 953-959; Schreinemakers, J.M.J., Vriens, M.R., Munoz-Perez, N., Fluorodeoxyglucose-positron emission tomography scan-positive recurrent papillary thyroid cancer and the prognosis and implications for surgical management (2012) World J Surg Oncol, 10, p. 192; Marcus, C., Antoniou, A., Rahmim, A., Fluorodeoxyglucose positron emission tomography/computerized tomography in differentiated thyroid cancer management: Importance of clinical justification and value in predicting survival (2015) J Med Imaging Radiat Oncol, 59, pp. 281-288; Ibanez, E.M., Muros, M.A., Torres Vela, E., The role of early 18F-FDG PET/CT in therapeutic management and ongoing risk stratification of high/intermediate-risk thyroid carcinoma (2016) Endocrine, 51, pp. 490-498

PY - 2017/10

Y1 - 2017/10

N2 - Background: To assess the long-term prognostic value of 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in patients with differentiated thyroid carcinoma (DTC) undergoing empiric radioiodine (RAI) therapy due to raising values of thyroglobulin (Tg). Methods: Forty-nine patients with histological diagnosis of DTC (31 with papillary and 18 with follicular carcinoma) follow-up for a mean period of 7.9±5 years after empiric RAI therapy were retrospectively analyzed. Results:FDG-PET/CT was negative in 15 (30.6%) patients and positive in 34 (69.4%), whereas postradioiodine therapy whole body scan (t-WBS) was negative in 16 (32.7%) and positive in 33 (67.3%) patients. FDG-PET/CT and t-WBS were in agreement in 32 patients (7 both negative and 25 both positive); on the contrary, in 17 patients there was disagreement between FDG-PET/CT and t-WBS (P=ns). At short-term follow-up, Tg normalized in 19 (38.8%) patients and was unchanged or increased in 30 (61.2%). Of the 15 patients with negative FDG-PET/CT, 11 (73.3%) showed Tg normalization, whereas of the 34 patients with positive FDG-PET/CT, only 8 (23.5%) had Tg normalization (x2=8.9, P<.005). At multivariate analysis, FDG-PET/CT and Tg normalization at short-term follow-up were independent predictors of disease-free survival (x2=26.3, P<.0001), while Tg normalization was the only variable associated with overall survival x2=7.2, P<.01). Conclusion: FDG-PET/CT in association with Tg normalization at short-term follow-up may be useful for long-term prognostic stratification in DTC patients.. © 2017 the Author(s). Published by Wolters Kluwer Health, Inc.

AB - Background: To assess the long-term prognostic value of 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in patients with differentiated thyroid carcinoma (DTC) undergoing empiric radioiodine (RAI) therapy due to raising values of thyroglobulin (Tg). Methods: Forty-nine patients with histological diagnosis of DTC (31 with papillary and 18 with follicular carcinoma) follow-up for a mean period of 7.9±5 years after empiric RAI therapy were retrospectively analyzed. Results:FDG-PET/CT was negative in 15 (30.6%) patients and positive in 34 (69.4%), whereas postradioiodine therapy whole body scan (t-WBS) was negative in 16 (32.7%) and positive in 33 (67.3%) patients. FDG-PET/CT and t-WBS were in agreement in 32 patients (7 both negative and 25 both positive); on the contrary, in 17 patients there was disagreement between FDG-PET/CT and t-WBS (P=ns). At short-term follow-up, Tg normalized in 19 (38.8%) patients and was unchanged or increased in 30 (61.2%). Of the 15 patients with negative FDG-PET/CT, 11 (73.3%) showed Tg normalization, whereas of the 34 patients with positive FDG-PET/CT, only 8 (23.5%) had Tg normalization (x2=8.9, P<.005). At multivariate analysis, FDG-PET/CT and Tg normalization at short-term follow-up were independent predictors of disease-free survival (x2=26.3, P<.0001), while Tg normalization was the only variable associated with overall survival x2=7.2, P<.01). Conclusion: FDG-PET/CT in association with Tg normalization at short-term follow-up may be useful for long-term prognostic stratification in DTC patients.. © 2017 the Author(s). Published by Wolters Kluwer Health, Inc.

KW - 18F-FDG-PET/CT

KW - differentiated thyroid carcinoma

KW - empiric therapy

KW - prognosis

KW - thyroglobulin

KW - fluorodeoxyglucose f 18

KW - iodine 131

KW - radioactive iodine

KW - radiopharmaceutical agent

KW - adult

KW - Article

KW - cancer diagnosis

KW - cancer patient

KW - cancer prognosis

KW - cancer survival

KW - clinical article

KW - differentiated thyroid cancer

KW - disease free survival

KW - female

KW - follow up

KW - histopathology

KW - human

KW - male

KW - medical record review

KW - middle aged

KW - overall survival

KW - positron emission tomography-computed tomography

KW - priority journal

KW - retrospective study

KW - thyroglobulin blood level

KW - thyroid follicular carcinoma

KW - thyroid papillary carcinoma

KW - whole body scintiscanning

KW - aged

KW - biosynthesis

KW - diagnostic imaging

KW - mortality

KW - pathology

KW - Thyroid Neoplasms

KW - Adult

KW - Aged

KW - Disease-Free Survival

KW - Female

KW - Fluorodeoxyglucose F18

KW - Humans

KW - Iodine Radioisotopes

KW - Male

KW - Middle Aged

KW - Positron Emission Tomography Computed Tomography

KW - Prognosis

KW - Radiopharmaceuticals

KW - Retrospective Studies

KW - Thyroglobulin

U2 - 10.1097/MD.0000000000008344

DO - 10.1097/MD.0000000000008344

M3 - Article

VL - 96

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 42

ER -